Steroid-Refractory Acute GVHD: Predictors and Outcomes

Area of Science:

• Hematology
• Immunology
• Oncology

Background:

• Acute graft versus host disease (aGVHD) poses a significant threat post-allogeneic hematopoietic stem cell transplantation (HSCT).
• Steroid-resistant aGVHD is associated with extremely high mortality rates, exceeding 90%.

Purpose of the Study:

• To identify patient subgroups unlikely to benefit from initial corticosteroid therapy for aGVHD.
• To evaluate the impact of treatment response on day 14 on patient outcomes.

Main Methods:

• Retrospective analysis of 287 patients with biopsy-proven aGVHD treated with corticosteroids post-allogeneic HSCT.
• Data collected from M.D. Anderson Cancer Center between 1998 and 2002.

Main Results:

• Overall response to first-line corticosteroid therapy by day 14 was 56%.
• Grade III-IV aGVHD and hyperacute GVHD were significant predictors of treatment failure.
• Lack of response by day 14 indicated a poor prognosis.

Conclusions:

• Patients failing to respond to steroids by day 14 warrant consideration for alternative therapies or clinical trials.
• Prognostic scoring systems incorporating aGVHD severity, hyperacute GVHD, and sex mismatch could aid in identifying patients unlikely to benefit from standard corticosteroid treatment.